On Aug. 19, 2016, InBios announced that it had received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its ZIKV Detect IgM Capture ELISA. This important diagnostic test kit contained all the necessary reagents to perform this assay and obtain results in four hours or less.

The product was intended for the presumptive detection of Zika virus IgM antibodies in human sera collected from individuals meeting CDC Zika virus clinical criteria (e.g., a history of clinical signs and symptoms associated with Zika virus infection) and/or CDC Zika virus epidemiological criteria.